- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06797635
Studie van Patritumab Deruxtecan plus pembrolizumab met andere antikankermiddelen bij deelnemers met een hoog-risico in een vroeg stadium triple-negatieve of hormoonreceptor-lage positieve/HER-2 negatieve borstkanker (MK-1022-010, Herthena-Breast-03)
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple- Negatieve of hormoonreceptor-lage positieve/menselijke epidermale groeifactor receptor-2 negatieve borstkanker (Herthena-Breast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
-
Córdoba, Spanje, 14004
- Werving
- Hospital Universitario Reina Sofia ( Site 1702)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34 957012408
-
-
Catalonia
-
Badalona, Catalonia, Spanje, 08916
- Werving
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34934978925
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanje, 28027
- Werving
- Clinica Universidad de Navarra ( Site 1703)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34913531920
-
-
-
-
-
Taichung, Taiwan, 407
- Werving
- Taichung Veterans General Hospital ( Site 2502)
-
Contact:
- Study Coordinator
- Telefoonnummer: +886423592525
-
Tainan, Taiwan, 704
- Werving
- National Cheng Kung University Hospital ( Site 2503)
-
Contact:
- Study Coordinator
- Telefoonnummer: +88662353535
-
Taipei, Taiwan, 112
- Werving
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
Contact:
- Study Coordinator
- Telefoonnummer: 886228970011x1686
-
-
-
-
California
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
Contact:
- Study Coordinator
- Telefoonnummer: 424-402-9520
-
-
Illinois
-
Skokie, Illinois, Verenigde Staten, 60077
- Werving
- Orchard Healthcare Research Inc. ( Site 0006)
-
Contact:
- Study Coordinator
- Telefoonnummer: 847-568-9932
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59102
- Werving
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
Contact:
- Study Coordinator
- Telefoonnummer: 406-238-6685
-
-
Oregon
-
Happy Valley, Oregon, Verenigde Staten, 97015
- Werving
- Northwest Cancer Specialists, P.C. ( Site 8003)
-
Contact:
- Study Coordinator
- Telefoonnummer: 360-944-9889
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- SCRI Oncology Partners ( Site 7000)
-
Contact:
- Study Coordinator
- Telefoonnummer: 844-482-4812
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75246
- Werving
- Texas Oncology - DFW ( Site 8000)
-
Contact:
- Study Coordinator
- Telefoonnummer: 214-370-1067
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- Houston Methodist Hospital ( Site 0022)
-
Contact:
- Study Coordinator
- Telefoonnummer: 713-441-9948
-
-
Virginia
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Virginia Oncology Associates (VOA) ( Site 8001)
-
Contact:
- Study Coordinator
- Telefoonnummer: 844-482-4812
-
-
-
-
-
Seoul, Zuid -Korea, 03080
- Werving
- Seoul National University Hospital ( Site 2400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82220720850
-
Seoul, Zuid -Korea, 05505
- Werving
- Asan Medical Center ( Site 2401)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82230103217
-
Seoul, Zuid -Korea, 03722
- Werving
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82222288135
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. |
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
|
|
Experimenteel: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Andere namen:
|
|
Experimenteel: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Andere namen:
|
|
Actieve vergelijker: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles. |
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Andere namen:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Tijdsspanne: Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1. |
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Tijdsspanne: Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity. |
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Tijdsspanne: Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1. |
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Tijdsspanne: Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
Tijdsspanne: Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2. |
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Tijdsspanne: Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2. |
Up to ~90 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Tijdsspanne: Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
Tijdsspanne: Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
Tijdsspanne: Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Tijdsspanne: Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
Tijdsspanne: Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28). |
Up to ~30 weeks
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Huidziektes
- Borst ziekten
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Nucleïnezuren, nucleotiden en nucleosiden
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Koolhydraten
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glycosiden
- Coördinatiecomplexen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Fosforamide mosterd
- Stikstofmosterdverbindingen
- Mosterdverbindingen
- Koolwaterstoffen, gehalogeneerd
- Fosforamides
- Organofosforverbindingen
- Nucleosiden
- Uracil
- Pyrimidinonen
- Antracyclines
- Naftacenes
- Aminoglycosides
- Daunorubicine
- Deoxyribonucleosides
- Fluorouracil
- Capecitabine
- Cyclofosfamide
- Carboplatine
- Doxorubicine
- Paclitaxel
- Epirubicine
- pembrolizumab
- Olaparib
- patritumab deruxtecan
Andere studie-ID-nummers
- 1022-010
- MK-1022-010 (Andere identificatie: MSD)
- U1111-1307-7867 (Register-ID: UTN)
- 2024-514376-40-00 (Register-ID: EU CT)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .